B. Metzler seel. Sohn & Co. AG Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA)

B. Metzler seel. Sohn & Co. AG trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 32.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 15,267 shares of the company’s stock after selling 7,406 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Moderna were worth $635,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. abrdn plc grew its position in Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Moderna by 30.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after purchasing an additional 23,881 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Moderna by 2,150.4% in the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after purchasing an additional 22,192 shares in the last quarter. Geode Capital Management LLC increased its stake in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after buying an additional 178,115 shares during the period. Finally, Proficio Capital Partners LLC boosted its position in Moderna by 4,418.9% in the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock valued at $6,127,000 after buying an additional 144,099 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 2.4 %

Shares of Moderna stock opened at $25.11 on Friday. The firm has a market cap of $9.71 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a 52-week low of $23.76 and a 52-week high of $170.47. The company’s 50-day simple moving average is $33.55 and its 200-day simple moving average is $43.01.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Leerink Partners dropped their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.